SUNSHINE BIOPHARMA IDENTIFIES A LEAD ANTI-CORONAVIRUS COMPOUND
October 07 2020 - 8:00AM
InvestorsHub NewsWire
SUNSHINE BIOPHARMA
IDENTIFIES A LEAD ANTI-CORONAVIRUS
COMPOUND
Montreal, Canada -- October
7, 2020 -- InvestorsHub NewsWire -- Sunshine Biopharma Inc.
(OTC Markets: “SBFM”),
a pharmaceutical company focused on the research, development and
commercialization of oncology and antiviral drugs today announced
that it has screened and subsequently identified a lead compound
from its library of Coronavirus protease inhibitors. The screening
which pinpointed the lead compound was performed at the University
of Georgia, College of Pharmacy under the leadership of Dr. Scott
D. Pegan, Director of the Center for Drug Discovery and Interim
Associate Head of Pharmaceutical and Biomedical Sciences. The
Company is currently looking into expanding its collaboration with
the University of Georgia and will be seeking the University’s
assistance in advancing the development of the newly identified
lead compound.
The compounds which were
screened are based on the technology described in Sunshine
Biopharma’s recently filed patent application covering small
molecules which can be used to treat Coronavirus infections. Next,
Sunshine’s lead compound will be put through a battery of in
vitro tests to evaluate its specific inhibitory activity
against the SARS-CoV-2 papain-like protease (PLpro), one of two
virus encoded proteases essential for viral replication. In
addition to cleaving the virus encoded polyprotein at three
different sites to generate mature virus proteins, PLpro also
cleaves certain host proteins resulting in suppression of the host
immune response and allowing virus replication to proceed unchecked
which enhances the virus’ ability to cause severe morbidity.
Following the in vitro tests, the lead compound will be
moved forward to the cell culture testing stage followed by mice
studies before entering human clinical
trials.
About Sunshine
Biopharma’s Coronavirus Treatment
Severe Acute Respiratory
Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of
COVID-19, the current ongoing pandemic that has claimed the lives
of over 1,000,000 people worldwide since it first appeared in
December 2019. There are currently no drugs that can effectively
arrest replication of the virus in people who have contracted the
illness. On May 22, 2020, Sunshine Biopharma filed a provisional
patent application for a library of molecules which were designed
to inhibit the Coronavirus proteases, thus shutting down the
ability of the virus to multiply and cause
illness.
About the University
of Georgia
As part of its land grant
tripartite mission, the University of Georgia is committed to
creating and applying new knowledge for the public good.
UGA’s Center for Drug Discovery as well as the Colleges of Pharmacy
are excited to be a part of this ground-breaking research related
to discovery of new treatment options for COVID-19. Profs. Scott
Pegan, and David Crich will be working with Sunshine Biopharma to
spearhead the study of novel therapeutics for the prevention and
spread of COVID-19. This interdisciplinary effort involves state of
the art approaches in chemical synthesis and drug screening. This
continues University of Georgia’s long-standing tradition in
translating scientific breakthroughs to address real world health
concerns.
About Sunshine
Biopharma
In addition, to working on
the development of a treatment for COVID-19, Sunshine Biopharma is
engaged in the development Adva-27a, a unique anticancer compound.
Tests conducted to date have demonstrated the effectiveness of
Adva-27a at destroying Multidrug Resistant Cancer Cells, including
Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast
Cancer cells, and Uterine Sarcoma cells. Clinical trials for
Pancreatic Cancer indication are planned to be conducted at McGill
University’s Jewish General Hospital in Montreal, Canada.
Sunshine Biopharma is owner of all patents and intellectual
property pertaining to Adva-27a.
Safe Harbor Forward-Looking
Statements
This press release may
contain forward looking statements which are based on current
expectations, forecasts, and assumptions that involve risks as well
as uncertainties that could cause actual outcomes and results to
differ materially from those anticipated or expected, including
statements related to the amount and timing of expected revenues
statements related to our financial performance, expected income,
distributions, and future growth for upcoming quarterly and annual
periods. These risks and uncertainties are further defined in
filings and reports by the Company with the U.S. Securities and
Exchange Commission (SEC). Actual results and the timing of
certain events could differ materially from those projected in or
contemplated by the forward-looking statements due to a number of
factors detailed from time to time in our filings with the SEC.
Among other matters, the Company may not be able to sustain growth
or achieve profitability based upon many factors including but not
limited to general stock market conditions. Reference is hereby
made to cautionary statements set forth in the Company's most
recent SEC filings. We have incurred and will continue to incur
significant expenses in our expansion of our existing as well as
new service lines noting there is no assurance that we will
generate enough revenues to offset those costs in both the near and
long term. Additional service offerings may expose us to
additional legal and regulatory costs and unknown exposure(s) based
upon the various geopolitical locations we will be providing
services in, the impact of which cannot be predicted at this
time.
For Additional
Information:
Sunshine Biopharma,
Inc.
Camille Sebaaly,
CFO
Direct Line:
514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com